×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACTU – actuate therapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACTU
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
08:00 am
actu
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
Low
Report
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
10/29
06:39 pm
actu
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
Medium
Report
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
9/23
08:00 am
actu
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3ß Inhibitor
Medium
Report
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3ß Inhibitor
9/16
08:00 am
actu
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
Medium
Report
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
9/11
08:00 am
actu
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Low
Report
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
9/9
08:00 am
actu
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Low
Report
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
9/5
09:10 am
actu
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
04:01 pm
actu
Form 10-Q ACTUATE THERAPEUTICS, For: Sep 30
Low
Report
Form 10-Q ACTUATE THERAPEUTICS, For: Sep 30
11/12
09:27 am
actu
Form 8-K ACTUATE THERAPEUTICS, For: Nov 12
Low
Report
Form 8-K ACTUATE THERAPEUTICS, For: Nov 12
9/24
04:06 pm
actu
Form 10-Q ACTUATE THERAPEUTICS, For: Jun 30
Medium
Report
Form 10-Q ACTUATE THERAPEUTICS, For: Jun 30
9/10
09:41 am
actu
Form SEC STAFF LETTER ACTUATE THERAPEUTICS,
Low
Report
Form SEC STAFF LETTER ACTUATE THERAPEUTICS,
9/10
09:41 am
actu
Form SEC STAFF LETTER ACTUATE THERAPEUTICS,
Low
Report
Form SEC STAFF LETTER ACTUATE THERAPEUTICS,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: